Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 62Carcinoma, Non-Small-Cell Lung 45Triple Negative Breast Neoplasms 24Ovarian Neoplasms 20Fallopian Tube Neoplasms 17Neoplasm Metastasis 16Lung Neoplasms 16Endometrial Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 12Esophageal Neoplasms 10Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 7Inflammatory Breast Neoplasms 6Head and Neck Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Carcinoma, Ovarian Epithelial 5Melanoma 4Carcinoma, Transitional Cell 4Carcinoma, Squamous Cell 4Adenocarcinoma Of Esophagus 4Urinary Bladder Neoplasms 3Peritoneal Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Lung Diseases 3

Interventions

lenvatinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Paclitaxel × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡